On September 15, 2020, Metacrine, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, announced the pricing of its initial public offering of 6,540,000 shares of its common stock at a public offering price of $13 per share. The company was approved for listing on the Nasdaq Global Market and began trading on September 16, 2020, under the ticker symbol “MTCR.”
Wilson Sonsini Goodrich & Rosati generally represents Metacrine in patent matters, including those related to the company's IPO. The Wilson Sonsini team that advised Metacrine in this transaction includes Michael Hostetler, Valentin Zunic, Uale Taotafa, and Jim Malecha.
For more information, please see Metacrine's press release.